127 Peachtree Street, N.E.
16 articles about Iconic Therapeutics
Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC).
Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor (TF) biology to new therapeutics for cancer, retinal disease and inflammation, today announced that Dirk Sauer, Ph.D., former Novartis Pharma AG’s Global Development Unit Head, Ophthalmology, has joined the company
Upfront payment and equity investment made to secure option on antibody for ophthalmology
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.
DECO Study to Explore Dosing Regimen with Higher ICON-1 Dose
Iconic Therapeutics, Inc. Announces Final Close Of Series C Financing With Additional $10 Million Investment